Payer Strategy & Managed Care
Expert articles and analysis related to payer strategy & managed care.
AI Summary — Last 30 Days
Synthesis: In the past 30 days, payer strategy in value-based care (VBC) has focused on scaling infrastructure and mitigating operational barriers as new federal models—such as the CMMI BALANCE program expanding GLP-1 access for obesity and comorbidities—push Medicare Advantage and ACOs toward broader population health management and digital quality reporting. Payers are prioritizing partnerships with providers who demonstrate scale and robust data capabilities, particularly in behavioral health, while initiatives like “Care Without Delay” and food-as-medicine pilots signal an acceleration of whole-person approaches under risk contracts. The ongoing tension between value-based incentives and the persistence of defensive medicine underscores the need for streamlined regulatory guides, sustained digital transformation, and increased physician engagement to realize the clinical and financial promise of these models (BALANCE program analysis; [Physician-mediation under risk](https://news.google.com/rss/articles/CBMi0AFBVV95cUxNclcxcmxMLVh5X1VHaVZhRUZVTkdxaDV6ZzhsMDVrcXZDV2RqOEluZnN0U21USHhkbnQ3a2NELTRnSEFQZmJwSG1lNk9SSlgwU1VPaHZkLWJpa1dTMjFBYXBFb2hUYW
Related Articles
STAT+: White House digs in on ‘most-favored nation’ drug pricing despite Congress’ cool reception
Despite a cool reception from Congress, the White House is looking to intensify its pressure campaign on lawmakers to pass a “most-favored nation" drug pricing bill.
STAT+: Asthma patients suffered as GSK pursued ‘egregious’ price hikes, senator says
After GSK replaced a popular asthma inhaler with an identical product at a higher price, families reported substantial financial and treatment problems, according to a new report.
Medicare Drug Price Negotiation: What Can We Learn From the 2027 Prices and Their Justifications?
Medicare Drug Price Negotiation: What Can We Learn From the 2027 Prices and Their Justifications? Health Affairs
15 drugs selected for Medicare negotiation program
15 drugs selected for Medicare negotiation program Becker's Hospital Review
Reimagining Prior Authorization: Increasing Transparency for Stakeholders
Reimagining Prior Authorization: Increasing Transparency for Stakeholders Fierce Healthcare
IRA Litigation: Pharma’s Failed Challenges To Medicare Drug Pricing
IRA Litigation: Pharma’s Failed Challenges To Medicare Drug Pricing Health Affairs
Panel: AI can improve prior authorization in healthcare but won’t solve all the issues
New approaches to prior authorization are crucial to improve a process that remains essential to supporting healthcare quality, according to a subject matter expert. “Prior auth exists because there’s...
Poll: Public Worries About Prescription Drug Costs Reach New High; Most Across Political Parties Want Government to Do More to Regulate Prices
As the Trump administration promotes its new TrumpRx website and other efforts to lower prescription drug prices, a growing majority of the public worries about being able to afford prescription drugs...
Public Views on Prescription Drug Costs: Regulation, Affordability and TrumpRx
Amid the Trump administration's focus on lowering prescription drug costs, including its new TrumpRx website, KFF's Health Tracking Poll finds that most Americans (59%) are worried about affording pre...
Families Scramble To Pay Five-Figure Bills as Clock Ticks on Promised Preauthorization Reforms
Last summer, the Trump administration announced a voluntary pledge by health insurers to reform prior authorization, which often requires patients or their doctors to seek preapproval from insurers be...